Maplewood, Minnesota-based Solventum Corporation (SOLV) is a healthcare company that develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. With a market cap of $12.7 billion, it operates in four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and SOLV fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the medical instruments & supplies industry. With a global presence in over 90 countries and a workforce of approximately 22,000 employees, Solventum is poised to leverage its rich history of innovation and deep market penetration to navigate the healthcare industry.

Despite its strengths, the stock has plunged 12.7% from its 52-week high of $85.92 touched on Feb. 26. Over the past three months, SOLV stock has grown 1.1%, outperforming the SPDR S&P Health Care Equipment ETF’s (XHE) 4.5% decline during the same time frame.

SOLV stock has grown 13.5% on a YTD basis, outperforming XHE’s 8.5% fall in 2025. Moreover, SOLV has surged 46.2% over the past 52 weeks, outperforming XHE’s 2.6% decline.

To confirm its bullish trend, SOLV has been trading above its 200-day and 50-day moving averages since early May.

SOLV stock rose 1.7% following the release of its better-than-expected Q1 2025 results on May 8. The company’s sales increased 2.7% year-over-year to $2.1 billion, driven by a growth in its MedSurg and HIS segments, and exceeded the Street's expectations. Moreover, its adjusted EPS decreased 35.6% from the prior-year quarter to $1.34, but surpassed the consensus estimates by 12.6%.

Its rival, Align Technology, Inc. (ALGN), has declined 10.5% in 2025 and 21.3% over the past year, underperforming the stock.

Among the 11 analysts covering the SOLV stock, the consensus rating is a “Hold.” Its mean price target of $81.57 suggests an 8.8% upside potential from current price levels.